YPrime has acquired software development company Tryl to expand its expertise to support decentralised clinical trials.

Tryl’s patient engagement solution combines personalisation and applied behavioural science to increase engagement, cut down dropouts, and provide results in clinical trials. 

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

With the Tryl takeover, YPrime will gain access to all the development expertise, staff and intellectual properties and will merge with Patient Engagement Technologies solutions of the latter.

The tools of Tryl offer a tailored, predictive and relative experience to the complete journey of the patient. 

Furthermore, its engagement score could lower the rate of patient dropouts

YPrime CEO Shawn Blackburn said: “YPrime’s major priority has always been to anticipate the needs of tomorrow’s clinical trials and create powerful eClinical tools that simplify the lives of sponsors, sites, and patients. 

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

“This combination with Tryl helps us leap ahead in fulfilling our vision of creating the industry’s first-of-its-kind solution to help keep patients more informed and engaged throughout the entire clinical trial process, especially as our industry accelerates toward decentralised clinical trial models.”

The Tryl team uses established behavioural principles from other industries such as professional sports and consumer finance to boost patient adherence to trial protocols.

Its predictive analytics aid clinicians to intervene before the dropout of the study subjects. This method lowers the burden of participants while also increasing value for sponsors as well as researchers.

Tryl CEO Ian Greenfield said: “An ever-increasing focus on patient centricity demands an integrated approach to how patients are engaged. 

“YPrime has a strong vision for the future and by bringing together offerings from our two companies, we can create a novel solution that takes head on the most pressing challenges associated with attracting, engaging, and retaining patients.”

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Recognised with 2025 Excellence Awards for Research and Development and Marketing , Novotech converted FDA/EMA fast track designations into faster HDV trial timelines while translating complex HBV science into sponsor ready insights. Discover how this dual strength in execution and communication is reshaping liver disease clinical development.

Discover the Impact